CSL Shares Plunge Most Ever After Impairments, Profit Target Cut

CSL Ltd. shares plunged the most on record after the Australian biotechnology company cut its full-year profit outlook and flagged approximately $5 billion in additional impairments, with the interim chief executive warning that a turnaround will take longer than expected.

The sharp sell-off reflects investor concern over the scale of the impairments and the prolonged recovery timeline, which could pressure CSL's earnings and valuation multiples. For equity traders, such a dramatic price move often triggers stop-loss orders and increased volatility, making real-time price monitoring essential. Live stocks prices on NowPrice show how the market is reacting in real time, allowing traders to track the ongoing decline and assess support levels.

Looking ahead, markets will focus on CSL's next earnings report and any further guidance from management regarding the impairment details and strategic initiatives. Traders should also watch for analyst downgrades and potential sector-wide impacts on biotech stocks, as well as broader market sentiment toward Australian equities.